retatrutide.catalog.heroHeading retatrutide.common.inUkraine

Next-generation triple agonist · 40 mg pen · ALLUVI Healthcare

Retatrutide 40 mg by ALLUVI Healthcare — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg (40 mg total), 12 needles included, dosing instructions.

Next-generation triple agonist · 40 mg per pen · Synedica Laboratories · Made in Germany

Retatrutide 40 mg from Synedica Laboratories (Germany) — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg each (40 mg total), 12 needles 32g 4mm included, instruction manual. Once weekly. Kit lasts approximately 12 weeks on average.

Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE

Retatrutide 6 mg from PEN PEPTIDE — stabilized pen injector with triple agonist GLP-1/GIP/glucagon. 120 units of 50 mcg each. Starting dose for course initiation. MSSPT technology — stable formula.

Next-generation triple agonist · 12 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE

Retatrutide 12 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 120 units of 100 mcg each. Optimal for dose escalation phase. MSSPT technology.

Next-generation triple agonist · 20 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE

Retatrutide 20 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 200 units of 100 mcg each. Optimal for maintenance dosing. MSSPT technology.

Next-generation triple agonist · 40 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE

Retatrutide 40 mg by PEN PEPTIDE — stabilized pen injector with triple GLP-1/GIP/glucagon agonist. 200 units of 200 mcg each. Maximum volume for extended treatment course. MSSPT technology.